SPADA, FRANCESCA
SPADA, FRANCESCA
Cabozantinib in neuroendocrine tumours: tackling drug activity and resistance mechanisms
2023-01-01 Cella, CHIARA ALESSANDRA; Cazzoli, Riccardo; Fazio, Nicola; DE PETRO, Giuseppina; Gaudenzi, Germano; Carra, Silvia; Romanenghi, Mauro; Spada, Francesca; Grossi, Ilaria; Pallavicini, Isabella; Minucci, Saverio; Vitale, Giovanni
Lung carcinoids with high proliferative activity: Further support for the identification of a new tumor category in the classification of lung neuroendocrine neoplasms
2020-01-01 Rubino, M.; Scoazec, J. Y.; Pisa, E.; Faron, M.; Spaggiari, L.; Hadoux, J.; Spada, F.; Planchard, D.; Cella, C. A.; Leboulleux, S.; De Marinis, F.; Ducreux, M.; Lamartina, L.; Baudin, E.; Fazio, N.
Pharmacodynamics, clinical findings and approval status of current and emerging tyrosine-kinase inhibitors for pancreatic neuroendocrine tumors
2019-01-01 Fazio, N.; Cella, C. A.; Del Re, M.; Laffi, A.; Rubino, M.; Zagami, P.; Spada, F.
Predictive Markers of Response to Everolimus and Sunitinib in Neuroendocrine Tumors
2017-01-01 Martins, D.; Spada, F.; Lambrescu, I.; Rubino, M.; Cella, C.; Gibelli, B.; Grana, C.; Ribero, D.; Bertani, E.; Ravizza, D.; Bonomo, G.; Funicelli, L.; Pisa, E.; Zerini, D.; Fazio, N.
Should platinum-based chemotherapy be preferred for germline BReast CAncer genes (BRCA) 1 and 2-mutated pancreatic ductal adenocarcinoma (PDAC) patients? A systematic review and meta-analysis
2019-01-01 Rebelatto, T. F.; Falavigna, M.; Pozzari, M.; Spada, F.; Cella, C. A.; Laffi, A.; Pellicori, S.; Fazio, N.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Cabozantinib in neuroendocrine tumours: tackling drug activity and resistance mechanisms | 1-gen-2023 | Cella, CHIARA ALESSANDRA; Cazzoli, Riccardo; Fazio, Nicola; DE PETRO, Giuseppina; Gaudenzi, Germano; Carra, Silvia; Romanenghi, Mauro; Spada, Francesca; Grossi, Ilaria; Pallavicini, Isabella; Minucci, Saverio; Vitale, Giovanni | |
| Lung carcinoids with high proliferative activity: Further support for the identification of a new tumor category in the classification of lung neuroendocrine neoplasms | 1-gen-2020 | Rubino, M.; Scoazec, J. Y.; Pisa, E.; Faron, M.; Spaggiari, L.; Hadoux, J.; Spada, F.; Planchard, D.; Cella, C. A.; Leboulleux, S.; De Marinis, F.; Ducreux, M.; Lamartina, L.; Baudin, E.; Fazio, N. | |
| Pharmacodynamics, clinical findings and approval status of current and emerging tyrosine-kinase inhibitors for pancreatic neuroendocrine tumors | 1-gen-2019 | Fazio, N.; Cella, C. A.; Del Re, M.; Laffi, A.; Rubino, M.; Zagami, P.; Spada, F. | |
| Predictive Markers of Response to Everolimus and Sunitinib in Neuroendocrine Tumors | 1-gen-2017 | Martins, D.; Spada, F.; Lambrescu, I.; Rubino, M.; Cella, C.; Gibelli, B.; Grana, C.; Ribero, D.; Bertani, E.; Ravizza, D.; Bonomo, G.; Funicelli, L.; Pisa, E.; Zerini, D.; Fazio, N. | |
| Should platinum-based chemotherapy be preferred for germline BReast CAncer genes (BRCA) 1 and 2-mutated pancreatic ductal adenocarcinoma (PDAC) patients? A systematic review and meta-analysis | 1-gen-2019 | Rebelatto, T. F.; Falavigna, M.; Pozzari, M.; Spada, F.; Cella, C. A.; Laffi, A.; Pellicori, S.; Fazio, N. |